Fri.May 24, 2024

article thumbnail

Latest Ozempic results 'move the needle' for treating patients with diabetes, chronic kidney disease: Novo exec

Fierce Pharma

While it’s hard to overstate the success Novo Nordisk’s GLP-1 franchise has already achieved, the company’s latest deep dive into semaglutide data in chronic kidney disease (CKD) could help set a n | Early Friday, Novo shared full, positive results from the FLOW trial assessing the ability of once-weekly semaglutide 1.0 mg to help combat major kidney outcomes such as kidney failure, loss of kidney function and death from kidney or cardiovascular causes in people with Type 2 diabetes and chronic

Patients 313
article thumbnail

Why Allegheny Health Network Created Its Own Chat-GPT For Employees

MedCity News

Allegheny Health Network rolled out a large language model designed exclusively for use by its staff members. You can think of the tool as the health system’s own version of Chat-GPT, said Ashis Barad, AHN’s chief digital and information officer. The post Why Allegheny Health Network Created Its Own Chat-GPT For Employees appeared first on MedCity News.

article thumbnail

Even after sharp sales drop, Pfizer sees bright side with priority review voucher from Paxlovid approval

Fierce Pharma

In a change of pace from the recent COVID-related business struggles for Pfizer, the drugmaker has picked up a valuable reward from the FDA in the form of a priority review voucher (PRV). | The FDA awarded the voucher based on Paxlovid's status as a countermeasure to a material medical threat, according to a notice in the Federal Register.

FDA 253
article thumbnail

ASCO: AffyImmune claims a first with CAR-T for solid tumours

pharmaphorum

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy. The case comes from a phase 1 study of its ICAM-1 targeting CAR-T autologous candidate AIC100 in patients with relapsed/refractory poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC), which will be reported at the ASCO congress next week.

Patients 118
article thumbnail

AI in Marketing & Sales: Today’s Tools, Tomorrow’s Potential

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

article thumbnail

Fierce Pharma Asia—AstraZeneca eyes China's innovation, plots Singapore ADC plant; FDA rejects Hengrui's PD-1 drug

Fierce Pharma

AstraZeneca's CEO wants to tap into China's innovation explosion. The company inked an oncology antibody deal with Harbour BioMed, and it plans to build a $1.5 billion ADC plant in Singapore. | AstraZeneca's CEO wants to tap into China's innovation explosion. The company inked an oncology antibody deal with Harbour BioMed, and it plans to build a $1.5 billion ADC plant in Singapore.

FDA 155
article thumbnail

Next-Generation Nursing

MedCity News

Virtual observation programs can help improve care, help better staff units, and help give nurses the support they need. The post Next-Generation Nursing appeared first on MedCity News.

113
113

More Trending

article thumbnail

MedCity Pivot Podcast: A Conversation With Walgreens’ Head of Specialty Drugs

MedCity News

Tracey James, chief operating officer of Walgreens’ specialty pharmacy business, talked about the retailer’s vision of innovating in the specialty pharmacy world, as well as about affordability and access. The post MedCity Pivot Podcast: A Conversation With Walgreens’ Head of Specialty Drugs appeared first on MedCity News.

Retail 109
article thumbnail

ASCO: Merus bispecific garners attention after abstract drop

pharmaphorum

Shares in Merus spike on ASCO abstract on phase 2 trial of EGFRxLGR5 bispecific petosemtamab in head and neck cancer.

110
110
article thumbnail

King’s Doctoral Training Centre to investigate MS symptom management

PharmaTimes

The lifelong autoimmune disease affects more than 150,000 people living in the UK

Doctors 109
article thumbnail

Lyra Health Announces Mental Health Offering for Teens

MedCity News

Lyra Care for Teens will be available starting in June. Patients will gain access to therapists who specialize in evidence-based treatments and personalized digital lessons. The post Lyra Health Announces Mental Health Offering for Teens appeared first on MedCity News.

article thumbnail

5 Ways You Can Win Faster with Gen AI in Sales

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

article thumbnail

ADC developer Pheon raises $120m, and other bio financings

pharmaphorum

This week’s round-up of biotech financings is led by a $120 million round for UK-based antibody-drug conjugate (ADC) developer Pheon, with SixPeaks also pulling in nine figures and smaller rounds for Progentos, LabGenius, and Grey Wolf, and Imvax.

105
105
article thumbnail

FDA advisory committee reviews Novo Nordisk insulin icodec for T1D

Pharmaceutical Technology

The US FDA's EMDAC is set to hold a meeting to assess the benefit-risk profile of Novo Nordisk's insulin icodec, to treat type 1 diabetes.

FDA 98
article thumbnail

New Phase III data for hidradenitis suppurativa biologic released

European Pharmaceutical Review

UCB has announced positive results from the first Phase III trials evaluating the efficacy and safety of an IL-17A and IL–17F inhibitor to treat adults with moderate-to-severe hidradenitis suppurativa. Humanised IgG1 monoclonal antibody (mAb) BIMZELX ® (bimekizumab-bkzx) selectively binds to IL-17A, IL-17F, and IL-17AF cytokines. This inhibits their interaction with the IL-17RA/IL-17RC receptor complex, UCB explained.

article thumbnail

Agenda announced for FlyPharma Vienna 2024

PharmaTimes

The conference will take place on 23 to 24 October at Vienna AirportCity

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Merck KGaA Announces $600 Million Deal to Acquire Mirus Bio

PharmaTech

With this acquisition, Merck KGaA will have the capability to offer integrated services for viral vector manufacturing.

article thumbnail

Therapy reprogrammes immune cells to shrink prostate and bladder cancers

PharmaTimes

JHU083 reduced tumour growth and triggered tumour cell death in mice

83
article thumbnail

ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody

Pharmaceutical Technology

Shares in Merus rose by 15% in premarket trading, following the announcement of positive Phase II data to be presented at ASCO.

72
article thumbnail

Eli Lilly Pumps $5.3B More Into Site for Making Metabolic Meds Zepbound & Mounjaro

MedCity News

Eli Lilly says its capital commitment to its new Indiana site is the largest manufacturing investment in the company’s history. The site will make tirzepatide, the active pharmaceutical ingredient in both Zepbound and Mounjaro. The post Eli Lilly Pumps $5.3B More Into Site for Making Metabolic Meds Zepbound & Mounjaro appeared first on MedCity News.

article thumbnail

10 Ways to Leverage Buyer Signals and Drive Revenue

In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.

article thumbnail

Study Finds Semaglutide Improves Chronic Kidney Disease in Patients With Type 2 Diabetes

Pharmacy Times

The role of semaglutide as a glucagon-like peptide-1 (GLP-1) receptor antagonist could offer further treatment options to improve patient outcomes.

article thumbnail

ASCO 2024: MediLink’s NSCLC and breast cancer ADC shows early safety success

Pharmaceutical Technology

The clinical-stage biotech will share preliminary safety and efficacy data with its ADC at the 2024 ASCO meeting.

Safety 59
article thumbnail

Pharma Pulse 5/24/24: Pre-Approval Information Exchange to Accelerate Product Success, Walgreens Boots Alliance Sells Shares of Cencora & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 59
article thumbnail

EC approves Celltrion’s Omlyclo for allergic conditions

Pharmaceutical Technology

The EC has approved Celltrion’s Omlyclo, an omalizumab biosimilar for reference product Xolair to treat allergic conditions.

59
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Pharmacy Closures Spark Need for PBM Reform

Pharmacy Times

Multiple states have enacted legislation to rein in PBM practices

58
article thumbnail

7 Tips for Providers to Improve Appointment Form Conversion Rates

Penrod

An online booking platform enables patients to schedule medical appointments efficiently and conveniently, alleviating the workload on your front office. However, merely having an online presence might not suffice in today’s competitive healthcare market. Your appointment forms likely need optimization. Improving your existing forms with a focus on conversion rates can lead to more patients and growing revenue.

article thumbnail

Pharmacists in Medical Cannabis Care Models: A Review

Pharmacy Times

As medical cannabis use grows, pharmacist involvement is essential.

Medical 55
article thumbnail

Orna Therapeutics Enhances Circular RNA Capabilities, Acquires ReNAgade Therapeutics

Pharmaceutical Commerce

The deal grows it pipeline, powered by panCAR programs in autoimmune disease and oncology.

52
article thumbnail

Signal-Based Selling: How to Leverage 4 Key Buying Signals

As prospects define their problem, search for solutions, and even change jobs, they are generating high-value signals that the best go-to-market teams can leverage to close more deals. This is where signal-based selling comes into play. ZoomInfo CEO Henry Schuck recently broke down specific ways to put four key buying signals into action with the experts from 30 Minutes to President’s Club.

article thumbnail

9 Patient Intake Mistakes Healthcare Providers Make During Acquisition

Penrod

1. Inefficient Appointment Scheduling An inefficient appointment scheduling system can lead to long wait times, double booking, and limited appointment availability, frustrating your existing and potential patients. These issues can disrupt the flow of your practice, causing dissatisfaction and potentially leading to a loss of patients. To solve this problem, you need a comprehensive booking system that offers consistency at each intake location.

article thumbnail

Biogen to Acquire HI-Bio in Deal Worth Potentially Up to $1.8 Billion

PharmaTech

With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases.

Leads 52
article thumbnail

Degron Therapeutics, Takeda Ink Exclusive License and Collaboration Agreement to Develop Molecule Degraders Targeting Multiple Indications

PharmExec

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52
article thumbnail

ASCO 2024: MSD’s ADC shows efficacy in lung and breast tumours

Pharmaceutical Technology

MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from China-based Sichuan Kelun-Biotech in 2022.

52
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven